ACOX1 and metabolic dysfunction-associated steatotic liver disease: These results suggest that ACOX1-specific inhibitors combined with middle or low-dose OCA may be a practical therapeutic approach for NAFLD, with potential benefits in improving transaminases, LDL and steatohepatitis in mice.